Tag Archives: type-industry &amp; policy

No account yet? Register

Aclipse Therapeutics Awarded AUD 1 Million Grant from FightMND

Aclipse Therapeutics Inc. was awarded an AUD 1 million drug development research grant from FightMND, the largest independent funder of amyotrophic lateral sclerosis (ALS) research in Australia. The grant supported the translational development of M102, a drug candidate for the treatment of ALS, also known as motor neuron disease or Lou Gehrig’s disease. M102 showed promise to stop and reverse ALS disease progression, as evidenced by data in preclinical models.

[Aclipse Therapeutics Inc (BusinessWire LLC)]

Abstract

No account yet? Register

UCLA Researchers’ Efforts to Combat Melanoma Gets $13M Boost From NIH

UCLA researchers have received a $13 million grant from the National Institutes of Health to find new ways to overcome melanoma resistance to some of the most promising targeted therapies and immunotherapies.

[University of California, Los Angeles]

No account yet? Register

ENHERTU^® Approved in Japan for the Treatment of Patients with HER2 Positive Metastatic Gastric Cancer

Daiichi Sankyo Company, Limited announced the approval of ENHERTU^{®, a HER2 directed antibody drug conjugate, in Japan for the treatment of patients with HER2 positive unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy.}

[Daiichi Sankyo Ltd.]

No account yet? Register

Celyad Oncology Announces Clinical Trial Collaboration to Evaluate CYAD-101 with KEYTRUDA^® (pembrolizumab) in Patients with Microsatellite Stable mCRC

Celyad Oncology SA, announced that the Company has entered into a clinical trial collaboration with MSD, a tradename of Merck & Co., Inc., through a subsidiary. Celyad Oncology will conduct the Phase Ib KEYNOTE-B79 clinical trial, which will evaluate Celyad Oncology’s investigational non-gene edited allogeneic CAR T candidate, CYAD-101, following FOLFIRI preconditioning chemotherapy, with MSD’s anti-PD-1 therapy, KEYTRUDA^® in refractory metastatic colorectal cancer patients with microsatellite stable/ mismatch-repair proficient disease.

[Celyad Oncology]

No account yet? Register

COVID-Vaccine Results Are on the Way – and Scientists’ Concerns Are Growing

Several ongoing coronavirus-vaccine trials could announce game-changing results next month. But as anticipation grows, concerns are growing about whether the vaccines will clear safety trials, what they will achieve if they do and the risk that the approval process will be influenced by politics, or at least seem to be.

[Nature News]

No account yet? Register

One Number Could Help Reveal How Infectious a COVID-19 Patient Is. Should Test Results Include It?

Now, epidemiologists and public health experts say testing centers should report not just whether a person is positive, but also a number known as the cycle threshold value, which indicates how much virus an infected person harbors.

[ScienceInsider]

No account yet? Register

AXIM^® Biotechnologies Receives Notice of US Patent Allowance for Proprietary Compounds and Methods Targeting Tumor Metastasis Through QSOX1

AXIM^® Biotechnologies, Inc. announced that the United States Patent and Trademark Office has issued the company a new Notice of Allowance for a patent on anti-neoplastic compounds and methods targeting Quiescin Sulfhydryl Oxidase 1, an enzyme important for tumor cell growth, invasion and metastasis.

[ AXIM Biotechnologies, Inc.]

No account yet? Register

Qihan Biotech Expands Scientific Advisory Board and Establishes Scientific Advisory Committees

Qihan Biotech has announced the expansion of its Scientific Advisory Board to include a total of 12 world-renowned experts in synthetic biology, regenerative medicine, transplantation immunology and cell therapy, as well as the formation of several Scientific Advisory Committees.

[Qihan Biotech (Businesswire, Inc.)]

No account yet? Register

Orgenesis Announces Agreement to Acquire Koligo Therapeutics, a Leader in Personalized Cell Therapies

Orgenesis Inc. and Koligo Therapeutics, Inc. have announced that the two companies have entered into a definitive merger agreement, subject to final closing conditions, with expected completion before year-end. Koligo’s lead clinical development program is for KT-PC-301, an autologous cell therapy containing a population of mesenchymal stem cells, vascular endothelial cells, and immune cells, under investigation for the treatment of COVID-19-related Acute Respiratory Disease Syndrome.

[Orgenesis Inc.]

No account yet? Register

FDA Approves KALYDECO^® (Ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants with CF as Early as Four Months of Age

Vertex Pharmaceuticals Incorporated announced the FDA approved KALYDECO^® for use in children with cystic fibrosis ages four months to less than six months old who have at least one mutation in their cystic fibrosis transmembrane conductance regulator gene that is responsive to KALYDECO based on clinical and/or in vitro assay data.

[Vertex Pharmaceuticals Incorporated]